FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2976099805> ?p ?o ?g. }

• W2976099805 abstract "It has been suggested that the severity of autism spectrum disorder (ASD) symptoms is positively correlated with the level of circulating or stored toxic metals, and that excretion of these heavy metals, brought about by the use of pharmaceutical chelating agents, results in improved symptoms.To assess the potential benefits and adverse effects of pharmaceutical chelating agents (referred to as chelation therapy throughout this review) for autism spectrum disorder (ASD) symptoms.We searched the following databases on 6 November 2014: CENTRAL, Ovid MEDLINE, Ovid MEDLINE In-Process, Embase,PsycINFO, Cumulative Index to Nursing and Allied Health Literature (CINAHL) and 15 other databases, including three trials registers. In addition we checked references lists and contacted experts.All randomised controlled trials of pharmaceutical chelating agents compared with placebo in individuals with ASD.Two review authors independently selected studies, assessed them for risk of bias and extracted relevant data. We did not conduct a meta-analysis, as only one study was included.We excluded nine studies because they were non-randomised trials or were withdrawn before enrolment.We included one study, which was conducted in two phases. During the first phase of the study, 77 children with ASD were randomly assigned to receive seven days of glutathione lotion or placebo lotion, followed by three days of oral dimercaptosuccinic acid (DMSA). Forty-nine children who were found to be high excreters of heavy metals during phase one continued on to phase two to receive three days of oral DMSA or placebo followed by 11 days off, with the cycle repeated up to six times. The second phase thus assessed the effectiveness of multiple doses of oral DMSA compared with placebo in children who were high excreters of heavy metals and who received a three-day course of oral DMSA. Overall, no evidence suggests that multiple rounds of oral DMSA had an effect on ASD symptoms.This review included data from only one study, which had methodological limitations. As such, no clinical trial evidence was found to suggest that pharmaceutical chelation is an effective intervention for ASD. Given prior reports of serious adverse events, such as hypocalcaemia, renal impairment and reported death, the risks of using chelation for ASD currently outweigh proven benefits. Before further trials are conducted, evidence that supports a causal link between heavy metals and autism and methods that ensure the safety of participants are needed." @default.
• W2976099805 created "2019-10-03" @default.
• W2976099805 creator A5029128792 @default.
• W2976099805 creator A5036875819 @default.
• W2976099805 creator A5051508365 @default.
• W2976099805 creator A5076197562 @default.
• W2976099805 date "2013-10-11" @default.
• W2976099805 modified "2023-10-18" @default.
• W2976099805 title "Chelation for autism spectrum disorder (ASD)" @default.
• W2976099805 cites W1508470722 @default.
• W2976099805 cites W1575709541 @default.
• W2976099805 cites W1698677017 @default.
• W2976099805 cites W1705638677 @default.
• W2976099805 cites W1746011489 @default.
• W2976099805 cites W1874279680 @default.
• W2976099805 cites W1967578162 @default.
• W2976099805 cites W1986682398 @default.
• W2976099805 cites W1994238140 @default.
• W2976099805 cites W1996586383 @default.
• W2976099805 cites W2003753209 @default.
• W2976099805 cites W2011126385 @default.
• W2976099805 cites W2016898594 @default.
• W2976099805 cites W2022702711 @default.
• W2976099805 cites W2023803903 @default.
• W2976099805 cites W2044931397 @default.
• W2976099805 cites W2045529153 @default.
• W2976099805 cites W2049028881 @default.
• W2976099805 cites W2069931937 @default.
• W2976099805 cites W2078189481 @default.
• W2976099805 cites W2087404899 @default.
• W2976099805 cites W2094797363 @default.
• W2976099805 cites W2097614044 @default.
• W2976099805 cites W2103317879 @default.
• W2976099805 cites W2104912466 @default.
• W2976099805 cites W2104945061 @default.
• W2976099805 cites W2114876457 @default.
• W2976099805 cites W2119643830 @default.
• W2976099805 cites W2123168228 @default.
• W2976099805 cites W2125183678 @default.
• W2976099805 cites W2126056720 @default.
• W2976099805 cites W2130235475 @default.
• W2976099805 cites W2140332754 @default.
• W2976099805 cites W2142056742 @default.
• W2976099805 cites W2157823046 @default.
• W2976099805 cites W2166439728 @default.
• W2976099805 cites W2167684047 @default.
• W2976099805 cites W2167943688 @default.
• W2976099805 cites W4206562851 @default.
• W2976099805 cites W4322695776 @default.
• W2976099805 doi "https://doi.org/10.1002/14651858.cd010766" @default.
• W2976099805 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/26106752" @default.
• W2976099805 hasPublicationYear "2013" @default.
• W2976099805 type Work @default.
• W2976099805 sameAs 2976099805 @default.
• W2976099805 citedByCount "10" @default.
• W2976099805 countsByYear W29760998052015 @default.
• W2976099805 countsByYear W29760998052016 @default.
• W2976099805 countsByYear W29760998052017 @default.
• W2976099805 countsByYear W29760998052019 @default.
• W2976099805 countsByYear W29760998052020 @default.
• W2976099805 countsByYear W29760998052021 @default.
• W2976099805 countsByYear W29760998052022 @default.
• W2976099805 crossrefType "reference-entry" @default.
• W2976099805 hasAuthorship W2976099805A5029128792 @default.
• W2976099805 hasAuthorship W2976099805A5036875819 @default.
• W2976099805 hasAuthorship W2976099805A5051508365 @default.
• W2976099805 hasAuthorship W2976099805A5076197562 @default.
• W2976099805 hasBestOaLocation W29760998051 @default.
• W2976099805 hasConcept C118552586 @default.
• W2976099805 hasConcept C126322002 @default.
• W2976099805 hasConcept C142724271 @default.
• W2976099805 hasConcept C168563851 @default.
• W2976099805 hasConcept C17744445 @default.
• W2976099805 hasConcept C187212893 @default.
• W2976099805 hasConcept C197934379 @default.
• W2976099805 hasConcept C199539241 @default.
• W2976099805 hasConcept C204787440 @default.
• W2976099805 hasConcept C205778803 @default.
• W2976099805 hasConcept C27081682 @default.
• W2976099805 hasConcept C2777218474 @default.
• W2976099805 hasConcept C2777799968 @default.
• W2976099805 hasConcept C2778538070 @default.
• W2976099805 hasConcept C2779473830 @default.
• W2976099805 hasConcept C2779549880 @default.
• W2976099805 hasConcept C71924100 @default.
• W2976099805 hasConcept C95190672 @default.
• W2976099805 hasConceptScore W2976099805C118552586 @default.
• W2976099805 hasConceptScore W2976099805C126322002 @default.
• W2976099805 hasConceptScore W2976099805C142724271 @default.
• W2976099805 hasConceptScore W2976099805C168563851 @default.
• W2976099805 hasConceptScore W2976099805C17744445 @default.
• W2976099805 hasConceptScore W2976099805C187212893 @default.
• W2976099805 hasConceptScore W2976099805C197934379 @default.
• W2976099805 hasConceptScore W2976099805C199539241 @default.
• W2976099805 hasConceptScore W2976099805C204787440 @default.
• W2976099805 hasConceptScore W2976099805C205778803 @default.
• W2976099805 hasConceptScore W2976099805C27081682 @default.
• W2976099805 hasConceptScore W2976099805C2777218474 @default.
• W2976099805 hasConceptScore W2976099805C2777799968 @default.
• W2976099805 hasConceptScore W2976099805C2778538070 @default.

• next